This is a summary of the European public assessment report (EPAR). It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the studies performed, to reach its recommendations on how to use the medicine. If you need more information about your medical condition or your treatment, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. If you want more information on the basis of the CHMP recommendations, read the scientific discussion (also part of the EPAR).
Therapeutic Indication
Circadin is indicated as monotherapy for the short\-term treatment of primary insomnia characterised by poor quality of sleep in patients who are aged 55 or over.
Therapeutic Area (MeSH)
ATC Code
N05CH01
ATC Item
N/A
Pharmacotherapeutic Group
Psycholeptics
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| melatonin | N/A | melatonin |
EMA Name
Circadin
Medicine Name
Circadin
Aliases
N/ANo risk management plan link.
